Table 2.

Determining Factors of the Antibody Responses to Pneumococcal Vaccines in Women With HIV

Serotype	Variable	No. Used	Linear Regressiona		Logistic Regressiona
					≥2-Fold Rise		≥0.35 µg/mL		≥1 µg/mL		≥4 µg/mL
			Coefficient (95% CI)	P Value	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value
1	PCV-10 vs PPV-23	317	−0.26 (−.35 to −.17)	<.001					0.38 (.22–.68)	.001	0.25 (.13–.46)	<.001
	Antepartum vs postpartum	317	−0.25 (−.35 to −.16)	<.001					0.52 (.27–1.00)	.049	0.31 (.17–.57)	<.001
	Prevaccine antibodiesb	317	0.05 (.04–.06)	<.001	0.80 (.75–.87)	<.001	1.42 (1.24–1.63)	<.001	1.32 (1.22–1.42)	<.001	1.22 (1.14–1.31)	<.001
	Prevaccine HIV RNA	317	−0.09 (−.15 to −.04)	0.001							0.50 (.31–.81)	.005
	Prevaccine CD4 countsc	317			1.17 (1.04–1.33)	.010			1.22 (1.09–1.37)	<.001
4	PCV-10 vs PPV-23	313	0.40 (.31–.49)	<.001	5.35 (2.77–10.30)	<.001	5.59 (1.82–17.17)	.003	7.57 (3.94–14.55)	<.001	7.22 (3.83–13.60)	<.001
	Antepartum vs postpartum	313	−0.17 (−.27 to −.07)	<.001	0.37 (.18–.75)	.006	0.25 (.06–.97)	.045	0.47 (.23–.95)	.035
	Prevaccine antibodiesb	313	0.07 (.06–.08)	<.001	0.85 (.79–.93)	<.001	1.77 (1.40–2.25)	<.001	1.44 (1.29–1.60)	<.001	1.33 (1.22–1.45)	<.001
	Prevaccine HIV RNA	313	−0.10 (−.16 to −.04)	<.001					0.43 (.29–.65)	<.001
	Prevaccine CD4 countsc	313									1.15 (1.04–1.26)	.007
5	Antepartum vs postpartum	322	−0.19 (−.28 to −.10)	<.001	0.41 (.25–.68)	<.001	0.27 (.09–.85)	.025	0.27 (.14–.54)	<.001	0.33 (.17–.65)	.001
	Prevaccine antibodiesb	322	0.08 (.07–.09)	<.001	0.90 (.85–.95)	<.001	1.97 (1.63–2.38)	<.001	1.60 (1.44–1.79)	<.001	1.32 (1.19–1.46)	<.001
6B	PCV-10 vs PPV-23	322			0.56 (.33–.96)	.033
	Antepartum vs postpartum	322			0.39 (.20–.74)	.004			0.38 (.17–.87)	.021
	Prevaccine antibodiesb	322	0.08 (.07–.09)	<.001	0.92 (.87–.97)	0.004	1.62 (1.38–1.91)	<.001	1.54 (1.39–1.72)	<.001	1.29 (1.21–1.37)	<.001
7F	PCV-10 vs PPV-23	322	−0.12 (−.21 to −.03)	0.011					0.52 (.30–.89)	.017	0.51 (.28–.93)	.027
	Antepartum vs postpartum	322							0.53 (.29–.98)	.043
	Prevaccine antibodiesb	322	0.07 (.06–.09)	<.001	0.90 (.84–.96)	.002	1.69 (1.41–2.02)	<.001	1.41 (1.29–1.54)	<.001	1.32 (1.21–1.45)	<.001
	Prevaccine CD8 countsc	322			0.92 (.85–1.00)	.049
14	PCV-10 vs PPV-23	322			0.55 (.32–.94)	.029
	Prevaccine antibodiesb	322	0.06 (.05–.07)	<.001	0.90 (.87–.94)	<.001	1.46 (1.24–1.71)	<.001	1.42 (1.26–1.59)	<.001	1.30 (1.22–1.38)	<.001
	Prevaccine CD4 countsc	322	0.03 (.01–.05)	.010	1.12 (1.01–1.25)	.029
23F	Antepartum vs postpartum	314	−0.16 (−.26 to −.05)	.005	0.34 (.17–.66)	.001					0.50 (.28–.90)	.020
	Prevaccine antibodiesb	314	0.08 (.07–.09)	<.001	0.92 (.87–.98)	.009	1.61 (1.36–1.89)	<.001	1.49 (1.36–1.64)	<.001	1.28 (1.19–1.38)	<.001
	Prevaccine CD8 countsc	314	−0.02 (−.03 to −.004)	.014	0.91 (.84–.99)	.021
33Fd	Antepartum vs postpartum	155	−0.23 (−.39 to −.08)	.003					0.26 (.07–.93)	.039
	Prevaccine antibodiesb	155	0.07 (.06–.09)	<.001			1.63 (1.07–2.50)	.024	1.38 (1.18–1.61)	<.001	1.31 (1.18–1.45)	<.001
	Prevaccine HIV RNA	155	−0.12 (−.20 to −.04)	.005					0.52 (.32–.84)	.007
	Prevaccine CD4 countsc	155									1.29 (1.11–1.50)	.001
	Prevaccine CD8 countsc	155									0.83 (.73–.95)	.006

Only the variables significantly associated with the antibody responses are shown.

The regression analyses included vaccine type, antepartum vs postpartum administration; and antibody concentrations, plasma HIV RNA copies/mL, CD4⁺ and CD8⁺ T-cell counts prevaccination.

For 0.1 log₁₀ µg/mL.

For 100 cells/mm³.

This serotype is present in the PPV-23 vaccine only.